The study for the efficacy of the combine therapy with proton pump inhibitor and irsogladine for the post-endoscopic submucosal dissection (ESD) gastric ulcer

The study for the efficacy of the combine therapy with proton pump inhibitor and irsogladine for the post-endoscopic submucosal dissection (ESD) gastric ulcer - The combined therapy with proton pump inhibitor and irsogladine for post-ESD gastric ulcer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008161

Enrollment

110

Registered

2012-06-13

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric ulcer

Interventions

Rabeprazole 10mg/day for 8 weeks p.o. Rabeprazole 10mg/day and Irsogladine 4mg/day p.o. for 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients over the age of 20 with gastric adenoma or early cancer who were referred to our hospital for the purpose of ESD

Exclusion criteria

Exclusion criteria: 1)Patients with repeated bleeding 2)major organ failure (such as cardiac and pulmonary complications) 3)Those with drug allergy 4)Concomitant administration of anticoagulants and antiinflammatory drugs 5)Patients with residual cancer histologically

Design outcomes

Primary

Measure	Time frame
Cure rates of gastric ulcer at 4 and 8 weeks of the treatment	—

Countries

Japan

Contacts

Public ContactRyoji Miyahara

Nagoya University Graduate School of Medicine Department of Gastroenterology and Hepatology

ryoji.miyahara@fujita-hu.ac.jp09058771669

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026